Founded in 2008, Beijing Health Guard Biotechnology, Inc. is a high-tech enterprise that is dedicated to the R&D and commercialization of innovative vaccines. As a top-tier player in the development of HPV vaccines in China, the Company boasts the most comprehensive HPV vaccine franchise worldwide that comprises a Trivalent, a Nonavalent and a 15-valent HPV vaccine, and has built a diversified vaccine pipeline with broad disease coverage. It is on the path to becoming a biopharma company.

The Company has completed interim analysis of the phase Ⅲ efficacy trial of the Trivalent HPV with positive data readout in August 2024, and a BLA submission therefor is expected in Q1 2025. The Company’s Nonavalent HPV is among the first homegrown nonavalent HPV vaccine candidates that have reached phase Ⅲ efficacy study in females in China, is the first and one of the only two homegrown HPV vaccines that have reached phase Ⅲ efficacy study in males, and is the only homegrown HPV vaccine that is under clinical development overseas. The Company expects to file a BLA for the Nonavalent HPV for use in females in both China and Indonesia in 2025, and a BLA for the Nonavalent HPV for use in males in 2027 in China.

Besides vaccine R&D, the Company also spares no effort to build advanced manufacturing capability. Currently, the Company has built an EU and China GMP-compliant pilot plant in Beijing for manufacturing vaccines used in pre-clinical and clinical studies, and is also constructing a manufacturing facility in Kunming for commercial production of HPV vaccines. The Kunming facility is designed to be compliant with world-class quality standards, including the GMP requirements of China, the EU and the WHO.

Since its inception, the Company has been certified as, among others, a High and New Technology Enterprise (HNTE) and a Beijing Specialized and Special New SMES.

The Company started to list on the Beijing Stock Exchange in March 2023 as the first innovative biotech start-up under the fourth set of listing standards. Shares of the Company are trading under the ticker Health Guard and stock code 833575.

The Company values collaboration opportunities with industry peers. In 2019, the Company and Liaoning Chengda Biotechnology Co., Ltd. entered into a collaboration agreement on the development and commercialization of the 15-valent HPV vaccine candidate. The Company will also actively respond to the Global Strategy to Accelerate the Elimination of Cervical Cancer launched by the WHO by working with global partners to make its effective and quality vaccines more accessible, thereby helping relieve the world from vaccine-preventable infectious diseases!